Literature DB >> 20688486

Impact of restricted amoxicillin/clavulanic acid use on Escherichia coli resistance--antibiotic DU90% profiles with bacterial resistance rates: a visual presentation.

Suzana Mimica Matanovic1, Ulf Bergman, Dubravka Vukovic, Björn Wettermark, Vera Vlahovic-Palcevski.   

Abstract

High use of amoxicillin/clavulanic acid (AMC) at the University Hospital Osijek (Croatia) contributed to high rates of resistance in Enterobacteriaceae, in particular Escherichia coli (50%). Thus, in order to decrease bacterial resistance, AMC use was restricted. We present results of the restriction on resistance amongst antibiotics accounting for 90% of antibiotic use [drug utilisation 90% (DU90%)]. Data were analysed on antibiotic use and microbiological susceptibility of E. coli during two 9-month periods, before and after the restriction of AMC use. Drug use was presented as numbers of defined daily doses (DDDs) and DDDs/100 bed-days. Resistance of E. coli to antibiotics was presented as percentages of isolated strains in the DU90% segment. Use of AMC was 16 DDDs/100 bed-days or 30% of all antibiotics before the intervention. Use of AMC fell to 2 DDDs/100 bed-days or 4% after the intervention, and resistance of E. coli fell from 37% to 11%. In conclusion, restricted use of AMC resulted in a significant decrease of E. coli resistance. DU90% resistance profiles are simple and useful tools in highlighting problems in antibiotic use and resistance but may also be useful in long-term follow-up of antibiotic policy. Copyright 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688486     DOI: 10.1016/j.ijantimicag.2010.05.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Adherence to hospital drug formularies and cost of drugs in hospitals in Denmark.

Authors:  Hanne T Plet; Jesper Hallas; Lene J Kjeldsen
Journal:  Eur J Clin Pharmacol       Date:  2013-06-14       Impact factor: 2.953

2.  Do educational meetings and group detailing change adherence to drug formularies in hospitals? A cluster randomized controlled trial.

Authors:  Hanne T Plet; Lene J Kjeldsen; René de Pont Christensen; Gitte S Nielsen; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

3.  Inhibitor-resistant TEM- and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates.

Authors:  Jesús Oteo; Juan José González-López; Adriana Ortega; J Natalia Quintero-Zárate; Germán Bou; Emilia Cercenado; María Carmen Conejo; Luis Martínez-Martínez; Ferran Navarro; Antonio Oliver; Rosa M Bartolomé; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

4.  A survey to assess knowledge, practice, and attitude of dentists in the Western region of Saudi Arabia.

Authors:  Maisa O Al-Sebaei; Ahmed M Jan
Journal:  Saudi Med J       Date:  2016-04       Impact factor: 1.484

5.  The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis.

Authors:  Emelie C Schuts; Anders Boyd; Anouk E Muller; Johan W Mouton; Jan M Prins
Journal:  Open Forum Infect Dis       Date:  2021-02-13       Impact factor: 3.835

6.  The appropriateness of antimicrobial use in the outpatient clinics of three hospitals in the Netherlands.

Authors:  Annemieke K van den Broek; Reinier M van Hest; Kamilla D Lettinga; Afra Jimmink; Fanny N Lauw; Caroline E Visser; Jan M Prins
Journal:  Antimicrob Resist Infect Control       Date:  2020-02-22       Impact factor: 4.887

7.  Improving the quality of antibiotic prescribing through an educational intervention delivered through the out-of-hours general practice service in Ireland.

Authors:  Nuala O'Connor; Roisin Breen; Mícheál Carton; Ina Mc Grath; Norma Deasy; Claire Collins; Akke Vellinga
Journal:  Eur J Gen Pract       Date:  2020-12       Impact factor: 1.904

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.